olivLaw · US equity research
BioNTech SE BNTX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
At the close of 30 Oct 2026, BioNTech SE (BNTX) stock was 88.17 USD (−1.08% on the day), with beta 0.93, 52-week range 83.89–119.34 USD.
Data as of · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 40.6
- weak (30–45)
- Bollinger (20, 2)
- 84.08 – 97.70
- in the lower half of the band · %B 0.30 · band width 15.0%
- SMA 50 / 200
- 97.24 / 97.10
- mixed trend
- MACD (12, 26, 9)
- -2.43 / -2.44
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.3% | −0.9% | −9.4 pp | — |
| 3 months | −2.7% | +1.2% | −3.9 pp | — |
| 6 months | −9.6% | +4.8% | −14.4 pp | — |
| Year to date | −7.4% | +10.7% | −18.1 pp | — |
| 1 year | −15.8% | +11.1% | −26.9 pp | +6.6% |
| 3 years | −5.7% | +80.7% | −86.5 pp | +68.3% |
| 5 years | −68.4% | +64.6% | −133.0 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 127.6 m | 108.6 m | 482.3 m | 19.0 bn | 17.3 bn | 3.8 bn | 2.8 bn | 2.9 bn |
| Revenue YoY | +107.1% | −14.9% | +344.1% | +3,834.6% | −8.8% | −77.9% | −28.0% | +4.3% |
| Net income | -48.0 m | -179.1 m | 15.2 m | 10.3 bn | 9.4 bn | 930.3 m | -665.3 m | -1.1 bn |
| Net income YoY | unavailable | unavailable | unavailable | +67,613.8% | −8.3% | −90.1% | −171.5% | unavailable |
| Diluted EPS | unavailable | -0.85 | 0.06 | 39.63 | 37.77 | 3.83 | -2.77 | -4.70 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | +65,950.0% | −4.7% | −89.9% | −172.3% | unavailable |
| net % | -37.6% | -164.9% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| Free cash flow | -88.8 m | -237.1 m | -79.5 m | 762.2 m | 13.2 bn | 5.1 bn | -78.8 m | 280.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.7 bn EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 19.2 bn EUR
- Total assets
- 22.0 bn EUR
- Debt / equity
- unavailable
- Current ratio
- 7.54x
- ROE
- -5.9%
- ROA
- -5.1%
- FCF margin
- 9.8%
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 482.3 m | 19.0 bn | 17.3 bn | 3.8 bn | 2.8 bn | 2.9 bn | SEC (XBRL)· 10 Mar 2026verified |
| Cost of revenue | 59.3 m | 2.9 bn | 3.0 bn | 599.8 m | 541.3 m | 641.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Gross profit | 423.0 m ≈ | 16.1 bn ≈ | 14.3 bn ≈ | 3.2 bn ≈ | 2.2 bn ≈ | 2.2 bn ≈ | SEC (XBRL)· 10 Mar 2026derived |
| Research & development | 645.0 m | 949.2 m | 1.5 bn | 1.8 bn | 2.3 bn | 2.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Operating income | -82.4 m | 15.3 bn | 12.6 bn | 690.4 m | -1.3 bn | -1.4 bn | SEC (XBRL)· 10 Mar 2026verified |
| Interest expense | 65.0 m | 305.1 m | 18.9 m | 23.9 m | 27.4 m | 69.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Pre-tax income | -145.8 m | 15.0 bn | 13.0 bn | 1.2 bn | -677.7 m | -1.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Income tax | -161.0 m | 4.8 bn | 3.5 bn | 255.8 m | -12.4 m | 85.3 m | SEC (XBRL)· 10 Mar 2026verified |
| Net income | 15.2 m | 10.3 bn | 9.4 bn | 930.3 m | -665.3 m | -1.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Diluted EPS | 0.06 | 39.63 | 37.77 | 3.83 | -2.77 | -4.70 | SEC (XBRL)· 10 Mar 2026verified |
| Weighted average diluted shares | 248.5 m | 259.7 m | 249.8 m | 242.7 m | 240.4 m | 241.7 m | SEC (XBRL)· 10 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 1.2 bn | 1.7 bn | 13.9 bn | 11.7 bn | 9.8 bn | 7.7 bn | SEC (XBRL)· 10 Mar 2026verified |
| Receivables | 165.5 m | 12.4 bn | 7.1 bn | 2.2 bn | 1.5 bn | 924.2 m | SEC (XBRL)· 10 Mar 2026verified |
| Inventories | 64.1 m | 502.5 m | 439.6 m | 357.7 m | 283.3 m | 110.7 m | SEC (XBRL)· 10 Mar 2026verified |
| Current assets | 1.7 bn | 15.1 bn | 21.9 bn | 19.5 bn | 18.8 bn | 16.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Property, plant & equipment, net | 227.0 m | 322.5 m | 609.2 m | 757.2 m | 935.3 m | 1.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Goodwill | 53.7 m | 57.8 m | 61.2 m | 362.5 m | 380.6 m | 367.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Total assets | 2.3 bn | 15.8 bn | 23.3 bn | 23.0 bn | 22.5 bn | 22.0 bn | SEC (XBRL)· 10 Mar 2026verified |
| Accounts payable | 102.3 m | 160.0 m | 204.1 m | 354.0 m | 426.7 m | 534.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Short-term debt | 9.1 m | 129.9 m | — | — | — | — | SEC (XBRL)· 30 Mar 2022verified |
| Long-term debt | 231.0 m | 171.6 m | — | — | — | — | SEC (XBRL)· 30 Mar 2022verified |
| Current liabilities | 606.0 m | 3.5 bn | 3.0 bn | 2.1 bn | 2.5 bn | 2.1 bn | SEC (XBRL)· 10 Mar 2026verified |
| Total liabilities | 946.8 m | 3.9 bn | 3.2 bn | 2.8 bn | 3.1 bn | 2.8 bn | SEC (XBRL)· 10 Mar 2026verified |
| Equity | 1.4 bn | 11.9 bn | 20.1 bn | 20.2 bn | 19.4 bn | 19.2 bn | SEC (XBRL)· 10 Mar 2026verified |
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.5 m | 889.7 m | 13.6 bn | 5.4 bn | 207.7 m | 456.0 m | SEC (XBRL)· 10 Mar 2026verified |
| Capex | 66.0 m | 127.5 m | 329.2 m | 249.4 m | 286.5 m | 175.1 m | SEC (XBRL)· 10 Mar 2026verified |
| Free cash flow | -79.5 m ≈ | 762.2 m ≈ | 13.2 bn ≈ | 5.1 bn ≈ | -78.8 m ≈ | 280.9 m ≈ | SEC (XBRL)· 10 Mar 2026derived |
| Investing cash flow | -144.8 m | -566.1 m | -35.3 m | -7.0 bn | -2.1 bn | -2.5 bn | SEC (XBRL)· 10 Mar 2026verified |
| Financing cash flow | 894.7 m | 94.2 m | -1.4 bn | -778.6 m | -45.9 m | -52.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Dividends paid | 0 | 0 | 484.3 m | 0 | 0 | — | SEC (XBRL)· 10 Mar 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 29.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
29% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -39.6% | 53 (vs peers) | 21% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -45.1% | 0 (on a fixed band) | 29% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -20.1x | 0 (on a fixed band) | 21% |
| Current ratio · Balance sheet | 7.5x | 100 (on a fixed band) | 14% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | 0.0% | 100 (on a fixed band) | 14% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial53/100 · 1/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BioNTech SE (BNTX). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 2.9 bn EUR in 2025; YoY growth 4.3%; net margin -39.6%; ROE -5.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 7.5x
- Payout ratio (FCF): 0.0%
What contradicts it
- Revenue CAGR 3Y: -45.1%
- Interest coverage: -20.1x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 251.9 bn | 28.9 | 91.5% | 23.0% | +10.0% | +56% / +82% |
| GILDGilead Sciences, Inc. | 211.7 bn | — | -22.3% | -12.5% | +2.4% | +42% / +117% |
| MRNAModerna, Inc. | 88.5 bn | — | -39.0% | -141.4% | −39.9% | +716% / +192% |
| RVMDRevolution Medicines, Inc. | 41.0 bn | — | -79.1% | — | unavailable | +225% / +866% |
| BIIBBiogen Inc. | 37.5 bn | 108.4 | 1.9% | 3.4% | +2.2% | +64% / +7% |
| MESOMesoblast Limited | 19.7 bn | — | -19.0% | -593.9% | +191.4% | −9% / +521% |
| EXELExelixis, Inc. | 16.9 bn | 20.7 | 44.3% | 35.5% | +7.0% | +79% / +237% |
| HALOHalozyme Therapeutics, Inc. | 14.9 bn | 38.6 | 173.7% | 24.9% | +37.6% | +101% / +287% |
| KRYSKrystal Biotech, Inc. | 9.8 bn | 41.7 | 20.1% | 54.8% | +33.9% | +68% / +184% |
| TWSTTwist Bioscience Corporation | 9.6 bn | — | -29.6% | -31.7% | +20.3% | +365% / +869% |
| CRSPCrispr Therapeutics AG | 5.0 bn | — | -26.1% | -3,368.7% | −90.6% | −20% / +32% |
| ADPTAdaptive Biotechnologies Corporation | 4.3 bn | — | -39.6% | -20.7% | +54.8% | +53% / +500% |
| TARSTarsus Pharmaceuticals, Inc. | 3.3 bn | — | -13.7% | -7.7% | +146.7% | +9% / +426% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.2 bn | — | — | -40.9% | +94.1% | +16% / +54% |
| VCELVericel Corporation | 2.1 bn | 95.3 | 7.2% | 7.9% | +16.5% | +15% / +14% |
| MAZEMaze Therapeutics, Inc. | 1.7 bn | — | -37.3% | -5,343.6% | unavailable | −4% / unavailable |
| INBXInhibrx Biosciences, Inc. | 1.1 bn | — | -1,773.6% | — | +550.0% | −12% / unavailable |
| GLUEMonte Rosa Therapeutics, Inc. | 918.0 m | — | -42.7% | -560.9% | +63.5% | −16% / +216% |
| MGTXMeiraGTx Holdings plc | 911.4 m | 13.4 | 72.2% | 19.9% | +144.6% | +5% / +110% |
| SLDBSolid Biosciences Inc. | 664.8 m | — | -65.5% | — | −40.6% | +15% / +178% |
| CADLCandel Therapeutics, Inc. | 637.4 m | — | -81.8% | — | 0.0% | +55% / +826% |
| ATYRaTYR PHARMA INC | 484.6 m | — | -98.4% | -32,003.7% | −19.1% | +470% / +295% |
| FENCFennec Pharmaceuticals Inc. | 359.1 m | — | -18.6% | -5.5% | −6.1% | +25% / +49% |
| XFORX4 Pharmaceuticals, Inc | 332.1 m | — | -113.1% | -1,040.1% | +150.0% | −17% / −86% |
| SABSSab Biotherapeutics, Inc. | 304.8 m | — | -11.3% | — | −100.0% | +3% / −67% |
1- and 3-year price returns: for BNTX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)22 Oct 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)13 Oct 2026
- Current report (foreign issuer)18 Sept 2026
- Current report (foreign issuer)14 Sept 2026
- Current report (foreign issuer)28 Aug 2026
- Current report (foreign issuer)27 Aug 2026
- Current report (foreign issuer)20 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.